Live
FierceBiotechJudge rules that HHS must face states' lawsuit over RFK Jr.'s agency overhaul, massive layoffsFierceBiotech'It’s going to be huge': The 'diabolical' molecule poised to become biotech's next gold rushFierceBiotechGilead pays Kymera $45M to glue preclinical protein degrader onto burgeoning oncology pipelineFierceBiotechBoehringer hands over funding, marketing rights for Click’s digital therapeuticFierceBiotechIn a first, a CAR-T cell therapy drives 3 autoimmune diseases into remission in a single patientBioPharma DiveChasing a tough-to-treat lung disease, Avalyn plans an IPOEndpoints NewsFDA lifts MacroGenics hold; Oxford and Bristol Myers team upBioPharma DiveLilly launches GLP-1 pill, kicking off showdown with Novo NordiskThermo FisherThermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PREC - PharmiWeb.comThermo FisherThermo Fisher, Singapore’s PRECISE Partner on Population-Scale Proteomics Biobank - Contract PharmaLonza NewsLonza Redefines Bioprocess Efficiency In APAC With Advanced Media Development Lab - BioSpectrum AsiaEndpoints NewsEveryone has a mental health chatbot. Now what?
FierceBiotech Apr 9, 2026

Gilead pays Kymera $45M to glue preclinical protein degrader onto burgeoning oncology pipeline

Gilead pays Kymera $45M to glue preclinical protein degrader onto burgeoning oncology pipeline

Original
Body unavailable. Use the original source.

Directory

59 All